Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Grants Orphan Drug Designation to LYT-200 in AML

March 13th 2024

The FDA has granted orphan drug designation to LYT-200 for the treatment of acute myeloid leukemia.

Treating Patients With Steroid-Refractory Chronic GvHD

March 13th 2024

Drs Safah and Cutler discuss treatment practices for patients with steroid-refractory graft-vs-host disease and highlight patients who are steroid dependent.

First-Line Therapy for Chronic GvHD

March 13th 2024

Hematologist-oncologists discuss the first-line treatment options for patients with chronic GvHD and the advantages and disadvantages of steroids.

Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib

March 13th 2024

Raajit K. Rampal, MD, PhD, discusses promising data on navtemadlin plus ruxolitinib for patients with myelofibrosis who had suboptimal responses to ruxolitinib, showing significant improvements in spleen and symptom responses, with further phase 3 studies anticipated.

Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1

March 13th 2024

Andrew Kuykendall, MD, reviews data from TRANSFORM-1 on navitoclax plus ruxolitinib for untreated myelofibrosis, highlighting consistent response rates, no significant symptom improvement with the combination, and challenges managing thrombocytopenia caused by navitoclax, despite its activity and potential as a second-line treatment option.

Challenges in Managing Adverse Events and Unmet Needs in Leukemia

March 12th 2024

Dr McCloskey highlights challenges in adverse event management and discusses unmet needs in the treatment of patients with leukemia.

Key Takeaways from Recent Updates in Leukemia

March 12th 2024

James K. McCloskey, MD, provides an overview of key takeaways from recent studies presented at the 2023 ASH Annual Meeting in leukemia.

Treatment Options and Unmet Needs in Higher-Risk MDS

March 12th 2024

Comprehensive insights on the current treatment landscape and remaining unmet needs for patients with higher-risk MDS.

Emerging Clinical Trials in MDS and Key Takeaways from ASH 2023

March 12th 2024

The panel discusses emerging clinical trials in the MDS treatment space and offers key takeaways from the 2023 ASH Annual Meeting.

TERN-701 Receives FDA Orphan Drug Designation in CML

March 12th 2024

TERN-701 has received orphan drug designation from the FDA for the treatment of patients with chronic myeloid leukemia.

Brentuximab Vedotin Plus Lenalidomide and Rituximab Generates OS Benefit in Previously Treated DLBCL

March 12th 2024

Brentuximab vedotin/lenalidomide/rituximab led to an OS improvement vs lenalidomide/rituximab/placebo in relapsed/refractory diffuse large B-cell lymphoma.

Coming Full Circle

March 12th 2024

Andrea Porpiglia, MD, MSc, FACS, and Sanjay Reddy, MD, FACS describe what makes the Complex General Surgical Oncology Fellowship at Fox Chase unique.

FDA Lifts Partial Clinical Hold on Trial Evaluating NX-2127 in R/R B-Cell Malignancies

March 11th 2024

The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies

Evolving With the Times

March 11th 2024

Jill Gilbert, MD, explains how publications must evolve to utilize modern educational platforms to reach readers.

FDA Approves Inotuzumab Ozogamicin for Pediatric CD22+ B-Cell Precursor Acute Lymphoblastic Leukemia

March 6th 2024

The FDA has approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2

March 6th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss how the combination of the BET inhibitor pelabresib and the JAK inhibitor ruxolitinib led to greater reductions in spleen size and symptoms compared to ruxolitinib alone in JAK inhibitor-naïve patients with intermediate- or high-risk myelofibrosis in the MANIFEST and MANIFEST-2 trials, with an acceptable safety profile, providing evidence that targeting multiple inflammatory pathways could lead to better disease control.

How JAK Inhibitors Have Shaped the Landscape of MF

March 6th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss how JAK inhibitors have reduced spleen size (splenomegaly) and constitutional symptoms like fatigue and fever in patients with myelofibrosis but that there is still room for improvement in treating other aspects of the disease like anemia and bone marrow fibrosis. They also share insights about the potential for combination therapies that target multiple pathways.

Clinicians Report Unmet Needs Regarding Training Fellows for Community-Based Careers

March 6th 2024

Clinicians say that there are substantial unmet needs in terms of deliberately training hematology/oncology fellows for community-based careers.

Staging Practices for Chronic Graft-vs-Host Disease

March 6th 2024

Hana Safah, MD, reviews the NIH staging system for graft-vs-host disease and discusses the importance of staging in determining prognosis and informing treatment decisions.

Role of Biomarkers in Graft-vs-Host Disease

March 6th 2024

Corey Cutler, MD, MPH, discusses the role of prognostic markers in graft-vs-host disease and how they can potentially inform treatment selection.